Last updated: February 24, 2026
What Is NDC 70000-0056?
NDC 70000-0056 corresponds to Imfinzi (durvalumab) injection, a PD-L1 immune checkpoint inhibitor developed by AstraZeneca. It is approved for tumor types including non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (SCLC), and bladder cancers.
Market Size and Growth Drivers
Current Market Overview
- Global Oncology Drug Market: Valued at approximately $195 billion in 2022, forecasted to grow at 6-8% annually through 2027[1].
- Durvalumab Specific Market: Estimated to achieve global sales of $2 billion in 2022, with expected growth driven by expanding indications and increasing adoption rates[2].
Key Market Drivers
- Expanded Approvals: Labels for additional indications in NSCLC, SCLC, and bladder cancer expand revenue opportunities.
- Unmet Medical Need: Patients with advanced or metastatic tumors benefit from immune checkpoint inhibitors, driving demand.
- Rising Prevalence: Lung and bladder cancers remain among the leading causes of cancer mortality.
Competitor Landscape
| Drug |
Indications |
2022 US Sales |
Market Share |
| Pembrolizumab (Keytruda) |
Multiple cancers, including NSCLC |
$9.8B |
35% |
| Atezolizumab (Tecentriq) |
NSCLC, SCLC, bladder cancer |
$2.4B |
9% |
| Durvalumab (Imfinzi) |
NSCLC, SCLC, bladder cancer |
$1.9B |
7% |
Price Analysis
Current Price Point
- Per Dose Cost: In the US, a typical 1,200 mg vial of Imfinzi costs approximately $6,100-$6,300 (wholesale acquisition cost)[3].
- Treatment Regimen: Usually administered every 4 weeks, with the typical course involving 6-12 doses depending on indication and patient response.
Pricing Trends
| Period |
Average Wholesale Price (AWP) per mg |
Notes |
| 2020 |
$5.20 |
Reflects initial market entry |
| 2022 |
$5.25-$5.35 |
Slight increase, consistent with inflation and dosing adjustments |
Price Projections (Next 3-5 Years)
- Assumptions:
- Slight price increase of 3-5% annually due to inflation and competitive dynamics.
- Potential discounts or rebates decreasing net prices by 15-20% for payers.
- Market expansion into new indications and markets could influence volume-based pricing strategies.
| Year |
Estimated Wholesale Price per mg |
Expected Trend |
| 2023 |
$5.40 |
2.5% rise over 2022 |
| 2025 |
$5.65 |
Cumulative 7.7% rise since 2022 |
| 2027 |
$5.90 |
Continued inflation, market growth |
Note: These projections are speculative, based on historical data and market trends.
Future Market Dynamics
- Biosimilars and Competition: As patents expire (expected 2029-2030), biosimilars could lower prices by 20-30%.
- Pricing Policies: Payer negotiations and value-based pricing models will influence actual transaction prices.
- Orphan and Rare Disease Markets: Smaller populations may see higher per-dose prices due to exclusivity, at least temporarily.
Investment Outlook and Commercial Viability
- The rising adoption of durvalumab is supported by clinical trials demonstrating improved survival.
- Price sensitivity remains moderate given the drug's clinical value; volume growth is more impactful than per-dose price increases.
- Market expansion and indication approvals will support revenue growth, although biosimilar competition threatens long-term margins.
Key Takeaways
- NDC 70000-0056 corresponds to Imfinzi, a key player in checkpoint immunotherapy for lung and bladder cancers.
- Market size is approximately $2 billion, with continued growth expected based on expanding indications.
- Wholesale prices hover around $6,100 per infusion (1200 mg vial), with minor annual increases.
- Price projections suggest a 2-3% annual increase over the next five years, balanced by potential biosimilar competition.
- Long-term profitability depends on indication expansion, market penetration, and patent status.
FAQs
1. How does Imfinzi compare pricing-wise to similar drugs?
Imfinzi's per mg cost is comparable to pembrolizumab but higher than atezolizumab, reflecting its positioning and clinical indications.
2. What factors could most influence future prices?
Patent exclusivity retention, biosimilar entry, payer negotiations, and regulatory changes.
3. How significant is the market for Imfinzi outside the US?
International markets account for approximately 40-50% of sales, with growth driven by emerging markets and expanding approvals.
4. What are the primary indications likely to drive future sales?
NSCLC, SCLC, and bladder cancer, especially with ongoing clinical trials for additional indications such as head and neck cancers.
5. How vulnerable is the pricing model to biosimilar competition?
Biosimilar entry could reduce prices by up to 30%, pressuring margins but also expanding access to broader patient populations.
References
- Deloitte. (2023). Global Healthcare Outlook.
- EvaluatePharma. (2022). Oncology Market Trends.
- Red Book. (2023). Wholesale Acquisition Cost Data.
